A Randomized, Double-blind, Placebo-controlled, 2-Injection, 52-Week Study to Evaluate the Efficacy and Safety of Intra-articular Injections of CNTX-4975-05 in Subjects With Chronic, Moderate-to-severe Osteoarthritis Knee Pain
Latest Information Update: 02 Jan 2024
At a glance
- Drugs Capsaicin (Primary)
- Indications Musculoskeletal pain
- Focus Registrational; Therapeutic Use
- Acronyms VICTORY-2
- Sponsors Centrexion Therapeutics
- 15 Nov 2023 Results of an analysis from combined data set from two studies (CNTX4975i-OA301 and CNTX4975i-OA304) reporting primary time point at week 12 with the numeric pain rating scale (Primary OA-301) between NPRS and WOMAC-A (Primary OA-304) presented at the ACR Convergence 2023
- 15 Nov 2023 Primary endpoint has not been met. (The Western Ontario and McMaster Universities Osteoarthritis Index Subscale A (pain) week 12), as per Results presented at the ACR Convergence 2023
- 15 Nov 2023 Results presented at the ACR Convergence 2023